DermaProtectは、皮膚むしり症(強迫性皮膚むしり)の管理を支援するために設計されたAI搭載のWebアプリケーションです。デバイスのウェブカメラを使用し、コンピュータービジョンでリアルタイムに顔を触る行動を検出し、カスタマイズ可能なアラートでその習慣を断ち切る手助けをします。このツールはCSIROが支援する研究を含む皮膚科学研究に基づいており、科学的に検証されたアプローチを提供します。
OpenSynapsは、AIを搭載したデジタルウェルネスプラットフォームで、ストレス、不安、恐怖症、依存症と戦うためのパーソナライズされたプログラムを提供します。催眠、ソフロロジー、瞑想、そして支援的なコミュニティを組み合わせ、ユーザーが静けさとバランスを取り戻すのを助けます。AIが個々のニーズに合わせてプログラムを調整し、真に個人的な治療体験を提供します。
製品概要
DermaProtect 製品概要
DermaProtectは、皮膚むしり症(強迫性皮膚むしり)の管理を支援するために設計されたAI搭載のWebアプリケーションです。デバイスのウェブカメラを使用し、コンピュータービジョンでリアルタイムに顔を触る行動を検出し、カスタマイズ可能なアラートでその習慣を断ち切る手助けをします。このツールはCSIROが支援する研究を含む皮膚科学研究に基づいており、科学的に検証されたアプローチを提供します。
OpenSynaps 製品概要
OpenSynapsは、AIを搭載したデジタルウェルネスプラットフォームで、ストレス、不安、恐怖症、依存症と戦うためのパーソナライズされたプログラムを提供します。催眠、ソフロロジー、瞑想、そして支援的なコミュニティを組み合わせ、ユーザーが静けさとバランスを取り戻すのを助けます。AIが個々のニーズに合わせてプログラムを調整し、真に個人的な治療体験を提供します。
Detailed feature comparison
| Feature | DermaProtect | OpenSynaps |
|---|---|---|
| 主要カテゴリー | コンピュータビジョン | メンタルヘルス |
| 追加日 | 2025-08-02 | 2025-08-11 |
| 価格 | 有料 | フリーミアム |
| 公式サイト | www.dermaprotect.app | opensynaps.com |
| 製品タイプ | ウェブサイト | ウェブサイト |
| Performance data | ||
| ユーザー評価 | 未確認 | 未確認 |
| コメント | 0 | 0 |
| 月間訪問数 | 3.4K | 9.5K |
| 月間成長率 | 未確認 | 20% |
| お気に入り | 112 | 129 |
| Details | 詳細を見る | 詳細を見る |
DermaProtect vs OpenSynaps monthly traffic
Compare DermaProtect and OpenSynaps by monthly reach, traffic trend, visit depth, top regions, and acquisition sources.
How to interpret the traffic data
In the DermaProtect vs OpenSynaps monthly traffic comparison, DermaProtect currently shows 3.4K visits and OpenSynaps shows 9.5K; OpenSynaps has about 2.8 times the visible traffic of DermaProtect, an absolute difference of about 6.1K visits. This reflects visible reach, not feature quality or paid users.
Only OpenSynaps has complete third-party traffic details; DermaProtect uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
DermaProtect monthly traffic:
Latest traffic
OpenSynaps monthly traffic:
Latest traffic
Monthly traffic trend
- 2025/9: 8.2K 月間訪問数
- 2026/1: 4.8K 月間訪問数
- 2026/2: 2.7K 月間訪問数
- 2026/3: 5.3K 月間訪問数
- 2026/4: 7.9K 月間訪問数
- 2026/5: 9.5K 月間訪問数
主要地域
Top 5 countries/regions
| Country/region | Percentage | Traffic |
|---|---|---|
| 🇫🇷France | 53.76% | 5.1K |
| 🇪🇸Spain | 27.12% | 2.6K |
| 🇺🇸United States | 19.12% | 1.8K |
検索キーワード
Usage comparison
Compare the core capabilities of DermaProtect and OpenSynaps
DermaProtect Core features
OpenSynaps Core features
Use cases
DermaProtect Use cases
OpenSynaps Use cases
DermaProtect vs OpenSynaps:In-depth comparison and selection guidance
First decide whether the products solve the same kind of need
This in-depth DermaProtect vs OpenSynaps comparison uses only the product records, taxonomy, audience, traffic, and community signals available on this page. DermaProtect is primarily listed under “コンピュータビジョン”, while OpenSynaps is primarily listed under “メンタルヘルス”, so the first decision is whether your actual task matches their recorded scope.
The structured fields currently show these decision-relevant differences: Primary category (DermaProtect: コンピュータビジョン; OpenSynaps: メンタルヘルス); Pricing (DermaProtect: Paid; OpenSynaps: Freemium); Monthly visits (DermaProtect: 3.4K; OpenSynaps: 9.5K); Favorites (DermaProtect: 112; OpenSynaps: 129); Website (DermaProtect: www.dermaprotect.app; OpenSynaps: opensynaps.com). These facts are more useful for selection than brand visibility alone.
What market visibility and monthly traffic mean
In the DermaProtect vs OpenSynaps monthly traffic comparison, DermaProtect currently shows 3.4K visits and OpenSynaps shows 9.5K; OpenSynaps has about 2.8 times the visible traffic of DermaProtect, an absolute difference of about 6.1K visits. This reflects visible reach, not feature quality or paid users.
Only OpenSynaps has complete third-party traffic details; DermaProtect uses visits recorded inside ToolMage. These scopes cannot estimate market share directly, and on-site views should not be treated as the product’s total website traffic.
The current traffic scope is not sufficient for a reliable product ranking. Treat monthly visits as a market-interest signal, then decide using taxonomy, use cases, pricing, and a like-for-like trial rather than reading exposure as product capability.
Product positioning, use cases, and roles
DermaProtect and OpenSynaps currently overlap in shared categories: 習慣形成; shared tags: AIコーチ、メンタルヘルス、ウェルネス. This can place both on the same shortlist, but it does not prove equal implementation, depth, or cost.
DermaProtect's unique categories/tags are コンピュータビジョン、メンタルヘルス、行動変容、BFRB、皮膚むしり症、顔トラッキング、習慣トラッカー、スキンケア; OpenSynaps's are メンタルヘルス、ウェルネス、不安、催眠、瞑想、禁煙、セルフヘルプ、ソフロロジー. These unique fields are the strongest differentiators: validate the product whose recorded scope matches the task instead of following traffic alone.
What ratings, comments, and favorites can tell you
DermaProtect has no verified rating, 0 comments, 112 favorites, and 124 likes;OpenSynaps has no verified rating, 0 comments, 129 favorites, and 127 likes。
Neither product has enough rating or comment samples for a credible reputation ranking.
Selection guidance by actual need
When to evaluate DermaProtect first
Put DermaProtect on the priority trial list when the task aligns with “コンピュータビジョン” and especially コンピュータビジョン、メンタルヘルス、行動変容、BFRB、皮膚むしり症、顔トラッキング. This follows recorded positioning and does not imply unlisted capabilities are absent.
DermaProtect also currently records: pricing is paid, product type is website, 3.4K on-site monthly views, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
When to evaluate OpenSynaps first
Put OpenSynaps on the priority trial list when the task aligns with “メンタルヘルス” and especially メンタルヘルス、ウェルネス、不安、催眠、瞑想、禁煙. This follows recorded positioning and does not imply unlisted capabilities are absent.
OpenSynaps also currently records: pricing is freemium, product type is website, 9.5K verified monthly visits, no verified user rating. Verify any hard requirement around price, platform, or reach before trial, and do not let sparse review data substitute for testing.
How to validate the recommendation before deciding
The available data describes positioning, public visibility, and community signals, but it cannot prove output quality, speed, integration effort, privacy, or long-term cost in your workflow. Before deciding, run the same representative tasks in DermaProtect and OpenSynaps, then record completion time, accuracy, manual corrections, and the real paid threshold. A like-for-like trial turns this comparison into a defensible adoption decision.




